Leerink Swann Downgrades Pharmasset (VRUS) to Market Perform; A Befitting End to a Remarkable Biotech Story

Go back to Leerink Swann Downgrades Pharmasset (VRUS) to Market Perform; A Befitting End to a Remarkable Biotech Story